Pathogen-Reduced Plasma + Crystalloid Solutions
ApprovedTerminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout Pathogen-Reduced Plasma + Crystalloid Solutions
Pathogen-Reduced Plasma + Crystalloid Solutions is a approved stage product being developed by Cerus for Burns. The current trial status is terminated. This product is registered under clinical trial identifier NCT04681638. Target conditions include Burns.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04681638 | Approved | Terminated |
Competing Products
12 competing products in Burns
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R-Pdf/Gbb 0.01% gel | Johnson & Johnson | Phase 2 | 52 |
| Ceftolozane/tazobactam | Merck | Approved | 85 |
| linezolid | Pfizer | Phase 1 | 32 |
| Somatropin + 0.09% Saline Solution | Pfizer | Phase 2/3 | 64 |
| Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867) | Bayer | Phase 3 | 74 |
| cP12 | United Therapeutics | Phase 2 | 49 |
| cNP8 | United Therapeutics | Phase 1 | 30 |
| Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications | Viatris | Approved | 82 |
| Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin | Baxter | Phase 1/2 | 38 |
| I-020502 | Baxter | Phase 2 | 49 |
| NexoBrid + Gel Vehicle | MediWound | Phase 3 | 69 |
| NexoBrid | MediWound | Phase 3 | 69 |
Other Products from Cerus
Traditional Cryoprecipitate + Pathogen-Reduced CryoprecipitateApproved
77
S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood CellsPhase 3
69
S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - ControlPhase 3
69
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets. + Autologous apheresis Conventional untreated Platelet ComponentsPhase 2
44
INTERCEPT treated plateletsPhase 2
44